282 related articles for article (PubMed ID: 17717600)
1. B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.
Cozma D; Yu D; Hodawadekar S; Azvolinsky A; Grande S; Tobias JW; Metzgar MH; Paterson J; Erikson J; Marafioti T; Monroe JG; Atchison ML; Thomas-Tikhonenko A
J Clin Invest; 2007 Sep; 117(9):2602-10. PubMed ID: 17717600
[TBL] [Abstract][Full Text] [Related]
2. CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis.
Chung EY; Psathas JN; Yu D; Li Y; Weiss MJ; Thomas-Tikhonenko A
J Clin Invest; 2012 Jun; 122(6):2257-66. PubMed ID: 22546857
[TBL] [Abstract][Full Text] [Related]
3. B cell receptor-ERK1/2 signal cancels PAX5-dependent repression of BLIMP1 through PAX5 phosphorylation: a mechanism of antigen-triggering plasma cell differentiation.
Yasuda T; Hayakawa F; Kurahashi S; Sugimoto K; Minami Y; Tomita A; Naoe T
J Immunol; 2012 Jun; 188(12):6127-34. PubMed ID: 22593617
[TBL] [Abstract][Full Text] [Related]
4. Differential PAX5 levels promote malignant B-cell infiltration, progression and drug resistance, and predict a poor prognosis in MCL patients independent of CCND1.
Teo AE; Chen Z; Miranda RN; McDonnell T; Medeiros LJ; McCarty N
Leukemia; 2016 Mar; 30(3):580-93. PubMed ID: 26073757
[TBL] [Abstract][Full Text] [Related]
5. PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells.
Fazio G; Palmi C; Rolink A; Biondi A; Cazzaniga G
Cancer Res; 2008 Jan; 68(1):181-9. PubMed ID: 18172310
[TBL] [Abstract][Full Text] [Related]
6. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway.
Yu D; Allman D; Goldschmidt MH; Atchison ML; Monroe JG; Thomas-Tikhonenko A
Blood; 2003 Mar; 101(5):1950-5. PubMed ID: 12406913
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus.
Souabni A; Jochum W; Busslinger M
Blood; 2007 Jan; 109(1):281-9. PubMed ID: 16968900
[TBL] [Abstract][Full Text] [Related]
8. The B cell receptor promotes B cell activation and proliferation through a non-ITAM tyrosine in the Igalpha cytoplasmic domain.
Patterson HC; Kraus M; Kim YM; Ploegh H; Rajewsky K
Immunity; 2006 Jul; 25(1):55-65. PubMed ID: 16860757
[TBL] [Abstract][Full Text] [Related]
9. The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition.
Varano G; Raffel S; Sormani M; Zanardi F; Lonardi S; Zasada C; Perucho L; Petrocelli V; Haake A; Lee AK; Bugatti M; Paul U; Van Anken E; Pasqualucci L; Rabadan R; Siebert R; Kempa S; Ponzoni M; Facchetti F; Rajewsky K; Casola S
Nature; 2017 Jun; 546(7657):302-306. PubMed ID: 28562582
[TBL] [Abstract][Full Text] [Related]
10. B-Lymphoma cells with epigenetic silencing of Pax5 trans-differentiate into macrophages, but not other hematopoietic lineages.
Hodawadekar S; Yu D; Cozma D; Freedman B; Sunyer O; Atchison ML; Thomas-Tikhonenko A
Exp Cell Res; 2007 Jan; 313(2):331-40. PubMed ID: 17098231
[TBL] [Abstract][Full Text] [Related]
11. PAX5 tyrosine phosphorylation by SYK co-operatively functions with its serine phosphorylation to cancel the PAX5-dependent repression of BLIMP1: A mechanism for antigen-triggered plasma cell differentiation.
Inagaki Y; Hayakawa F; Hirano D; Kojima Y; Morishita T; Yasuda T; Naoe T; Kiyoi H
Biochem Biophys Res Commun; 2016 Jun; 475(2):176-81. PubMed ID: 27181361
[TBL] [Abstract][Full Text] [Related]
12. Identification of Pax5 as a target of MTA1 in B-cell lymphomas.
Balasenthil S; Gururaj AE; Talukder AH; Bagheri-Yarmand R; Arrington T; Haas BJ; Braisted JC; Kim I; Lee NH; Kumar R
Cancer Res; 2007 Aug; 67(15):7132-8. PubMed ID: 17671180
[TBL] [Abstract][Full Text] [Related]
13. PAX5 promotes pre-B cell proliferation by regulating the expression of pre-B cell receptor and its downstream signaling.
Xue K; Song J; Yang Y; Li Z; Wu C; Jin J; Li W
Mol Immunol; 2016 May; 73():1-9. PubMed ID: 27016671
[TBL] [Abstract][Full Text] [Related]
14. Biphenotypic bigenotypic lymphoma with simultaneous expression of PAX5/BSAP and B- and T-cell markers.
Hansson M; Jerkeman M; Dictor M
Eur J Haematol; 2007 Aug; 79(2):159-65. PubMed ID: 17635241
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic uses of Pax5 immunohistochemistry.
Feldman AL; Dogan A
Adv Anat Pathol; 2007 Sep; 14(5):323-34. PubMed ID: 17717432
[TBL] [Abstract][Full Text] [Related]
16. Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene.
Schebesta M; Pfeffer PL; Busslinger M
Immunity; 2002 Oct; 17(4):473-85. PubMed ID: 12387741
[TBL] [Abstract][Full Text] [Related]
17. Multiple isoforms of PAX5 are expressed in both lymphomas and normal B-cells.
Arseneau JR; Laflamme M; Lewis SM; Maïcas E; Ouellette RJ
Br J Haematol; 2009 Nov; 147(3):328-38. PubMed ID: 19725825
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma.
Renné C; Martin-Subero JI; Eickernjäger M; Hansmann ML; Küppers R; Siebert R; Bräuninger A
Am J Pathol; 2006 Aug; 169(2):655-64. PubMed ID: 16877363
[TBL] [Abstract][Full Text] [Related]
19. Isoforms of Pax5 and co-regulation of T- and B-cells associated genes influence phenotypic traits of ascetic cells causing Dalton's lymphoma.
Bharti B; Mishra R
Biochim Biophys Acta; 2011 Dec; 1813(12):2071-8. PubMed ID: 21854813
[TBL] [Abstract][Full Text] [Related]
20. Synthetic biology of B cell activation: understanding signal amplification at the B cell antigen receptor using a rebuilding approach.
Kulathu Y; Zuern C; Yang J; Reth M
Biol Chem; 2019 Mar; 400(4):555-563. PubMed ID: 30465710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
